SLC38A7 (SNAT7) is a sodium-coupled symporter that selectively cotransports sodium ions and amino acids, particularly L-glutamine and L-asparagine, from the lysosome into the cytoplasm 12. The transporter requires an acidic lysosomal lumen for optimal function 1. SLC38A7 is uniquely expressed in neurons, including GABAergic neurons, with axonal localization near synaptic clefts, suggesting roles in glutamate recycling and synaptic function 3. Beyond neuronal function, SLC38A7 participates in mTORC1 activation through amino acid sensing 14. In cancer biology, SLC38A7 promotes malignancy across multiple tumor types. In gastric cancer, SLC38A7 enhances cell viability, migration, and mitochondrial function through m6A-methylation-dependent stabilization 5. High SLC38A7 expression in lung adenocarcinoma and squamous cell carcinoma correlates with advanced disease stage, poor recurrence-free and overall survival, and serves as an independent prognostic factor 67. SLC38A7 expression also correlates with chemotherapy resistance in breast cancer and reduced patient survival 8. Additionally, genetic variants in SLC38A7 associate with diabetic retinopathy risk 4 and influence anastrozole plasma concentrations in breast cancer therapy 9, highlighting its clinical significance as a potential therapeutic target.